StockData
International Stem Cell CORP logo

International Stem Cell CORP (ISCO) income statement

ISCOOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.28+0.00 (+0.89%)

Close on Oct 19, 2026Market cap $2.27MP/E –Yield –

International Stem Cell CORP income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
55.0%
Operating margin
-4.7%
Net margin
-6.1%
Return on equity, FY2025
10.5%

Financial strength

Current ratio
0.79
Debt to equity
–
Debt to assets
–
Cash to current liabilities
21.8%

Valuation

P/E ratio
–
Price to sales
0.24
Price to book
–
Dividend yield
–

See a number that looks wrong?